Tianshui Zhongxing Bio-technologyLtd Management

Management criteria checks 2/4

Tianshui Zhongxing Bio-technologyLtd's CEO is Liang Liu, appointed in Mar 2012, has a tenure of 12.17 years. directly owns 0.67% of the company’s shares, worth CN¥19.42M. The average tenure of the management team and the board of directors is 8.8 years and 3.1 years respectively.

Key information

Liang Liu

Chief executive officer

CN¥2.2m

Total compensation

CEO salary percentage	n/a
CEO tenure	12.2yrs
CEO ownership	0.7%
Management average tenure	8.8yrs
Board average tenure	3.1yrs

Recent management updates

Recent updates

Tianshui Zhongxing Bio-technology Co.,Ltd. (SZSE:002772) Held Back By Insufficient Growth Even After Shares Climb 37%

Mar 15

CEO

Liang Liu (49 yo)

12.2yrs

Tenure

CN¥2,176,200

Compensation

Mr. Liang Liu serves as General Manager at Tianshui Zhongxing Bio-technology Co., Ltd. He had been the Chief Financial Officer and Deputy General Manager of Tianshui Zhongxing Bio-technology Co., Ltd. sinc...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Boshu Gao	Chairman	3.1yrs	CN¥2.16m	0.34% CN¥ 9.7m
Liang Liu	GM & Director	12.2yrs	CN¥2.18m	0.67% CN¥ 19.4m
Min Li	CFO & Financial Director	5.4yrs	CN¥1.33m	no data
Bin Yuan	Deputy General Manager	no data	CN¥1.43m	0.50% CN¥ 14.5m
Jinjun Zhou	Deputy General Manager	4.2yrs	CN¥2.05m	0.025% CN¥ 722.8k

8.8yrs

Average Tenure

49yo

Average Age

Experienced Management: 002772's management team is seasoned and experienced (8.8 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Boshu Gao	Chairman	3.1yrs	CN¥2.16m	0.34% CN¥ 9.7m
Liang Liu	GM & Director	12.2yrs	CN¥2.18m	0.67% CN¥ 19.4m
Lin Dang	Independent Director	2.3yrs	CN¥55.00k	no data
Bo Zhao	Supervisor	3.1yrs	no data	0.018% CN¥ 513.8k
Yufei Zhang	Director	3.1yrs	CN¥106.60k	no data
Guoqing Wang	Director	3.1yrs	CN¥145.10k	no data
Tianrong Zhang	Employee Representative Chairman of the Supervisory Committee	3.1yrs	no data	no data

3.1yrs

Average Tenure

44yo

Average Age

Experienced Board: 002772's board of directors are considered experienced (3.1 years average tenure).

Tianshui Zhongxing Bio-technologyLtd Management

Management criteria checks 2/4

Key information

Recent management updates

Tianshui Zhongxing Bio-technology Co.,Ltd., Annual General Meeting, Apr 16, 2024

Less than half of directors are independent

Less than half of directors are independent

Recent updates

First quarter 2024 earnings released: EPS: CN¥0.088 (vs CN¥0.50 in 1Q 2023)

Tianshui Zhongxing Bio-technology Co.,Ltd. to Report Q1, 2024 Results on Apr 26, 2024

Tianshui Zhongxing Bio-technology Co.,Ltd., Annual General Meeting, Apr 16, 2024

Full year 2023 earnings released: EPS: CN¥0.39 (vs CN¥0.40 in FY 2022)

Tianshui Zhongxing Bio-technology Co.,Ltd. (SZSE:002772) Held Back By Insufficient Growth Even After Shares Climb 37%

Investor sentiment improves as stock rises 19%

Investor sentiment deteriorates as stock falls 15%

Tianshui Zhongxing Bio-technology Co.,Ltd. to Report Fiscal Year 2023 Results on Mar 26, 2024

Third quarter 2023 earnings released: CN¥0.056 loss per share (vs CN¥0.36 profit in 3Q 2022)

Tianshui Zhongxing Bio-technology Co.,Ltd. to Report Q3, 2023 Results on Oct 28, 2023

Second quarter 2023 earnings released: CN¥0.002 loss per share (vs CN¥0.088 loss in 2Q 2022)

Tianshui Zhongxing Bio-technology Co.,Ltd. to Report First Half, 2023 Results on Aug 19, 2023

Upcoming dividend of CN¥0.30 per share at 2.8% yield

Investor sentiment improves as stock rises 17%

Full year 2022 earnings released: EPS: CN¥0.40 (vs CN¥0.14 in FY 2021)

Less than half of directors are independent

Investor sentiment improved over the past week

Third quarter 2022 earnings released: EPS: CN¥0.36 (vs CN¥0.16 loss in 3Q 2021)

Second quarter 2022 earnings released: CN¥0.088 loss per share (vs CN¥0.084 loss in 2Q 2021)

Tianshui Zhongxing Bio-Technology Co.,Ltd. Announces 2021 Final Profit Distribution Plan, Payable on 19 May 2022

Less than half of directors are independent

Tianshui Zhongxing Bio-technology Co.,Ltd. Approves Cash Dividend for 2021

Third quarter 2021 earnings released: CN¥0.16 loss per share (vs CN¥0.19 profit in 3Q 2020)

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Second quarter 2021 earnings released: CN¥0.084 loss per share (vs CN¥0.054 loss in 2Q 2020)

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Tianshui Zhongxing Bio-technology Co.,Ltd. (SZSE:002772) signed a letter of intent to acquire Guizhou Moutai Shengjiao Wine Industry Co., Ltd. from Liu Liangyue.

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS CN¥0.13 (vs CN¥0.22 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.56 (vs CN¥0.19 in FY 2019)

Tianshui Zhongxing Bio-technology Co.,Ltd. to Report Fiscal Year 2020 Results on Mar 26, 2021

New 90-day low: CN¥8.86

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

New 90-day high: CN¥11.30

New 90-day high: CN¥9.97

Third quarter earnings released

Tianshui Zhongxing Bio-technology Co.,Ltd. to Report Q3, 2020 Results on Oct 22, 2020

Tianshui Zhongxing Bio-technology Co.,Ltd. to Report First Half, 2020 Results on Aug 22, 2020

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age